Lipocine (NASDAQ:LPCN) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a research report sent to investors on Monday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Trading Up 3.5 %

NASDAQ:LPCN opened at $3.53 on Monday. The stock has a market capitalization of $18.89 million, a price-to-earnings ratio of -4.64 and a beta of 1.23. The firm has a fifty day simple moving average of $4.69 and a two-hundred day simple moving average of $4.68. Lipocine has a 12 month low of $3.20 and a 12 month high of $11.79.

Institutional Trading of Lipocine

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP bought a new stake in shares of Lipocine Inc. (NASDAQ:LPCN) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned 0.22% of Lipocine as of its most recent SEC filing. Hedge funds and other institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.